Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endocyte Inc (NASDAQ:ECYT)

2.21
Delayed Data
As of 4:00pm ET
 -0.04 / -1.78%
Today’s Change
1.98
Today|||52-Week Range
4.33
-13.33%
Year-to-Date
5 Cheap Breakout Stocks for Superb Returns
Mar 16 / Zacks.com - Paid Partner Content
Endocyte (ECYT) Shares March Higher, Can It Continue?
Mar 14 / Zacks.com - Paid Partner Content
Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4
Mar 14 / Zacks.com - Paid Partner Content
Endocyte (ECYT) Reports a Wider Q4 Loss
Mar 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close2.25
Today’s open2.25
Day’s range2.21 - 2.28
Volume144,208
Average volume (3 months)231,367
Market cap$95.6M
Dividend yield--
Data as of 4:00pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)-6.12%
Earnings growth (this year)-12.50%
Earnings growth (next 5 years)--
Revenue growth (last year)0.00%
P/E ratioNM
Price/Sales1,537.67
Price/Book0.70

Competitors

 Today’s
change
Today’s
% change
CRMECardiome Pharma Corp0.000.00%
NOVNNovan Inc-0.05-0.82%
ALIMAlimera Sciences Inc+0.03+2.08%
AGLEAeglea Bio Therapeut...+0.05+0.68%
Data as of 4:00pm ET, 03/24/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$70.0K
Annual profit (last year)-$43.9M
Net profit margin-62,696.53%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael A. Sherman
Chief Financial Officer
Michael T. Andriole
Corporate headquarters
West Lafayette, Indiana

Forecasts


Search for Jobs